JP7829035B2 - アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法 - Google Patents

アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法

Info

Publication number
JP7829035B2
JP7829035B2 JP2024528580A JP2024528580A JP7829035B2 JP 7829035 B2 JP7829035 B2 JP 7829035B2 JP 2024528580 A JP2024528580 A JP 2024528580A JP 2024528580 A JP2024528580 A JP 2024528580A JP 7829035 B2 JP7829035 B2 JP 7829035B2
Authority
JP
Japan
Prior art keywords
agt
hypertension
dsrna
present
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024528580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543496A5 (https=
JP2024543496A (ja
Inventor
シュ，ドンシュ
パトリック シャオ，ペンチェン
Original Assignee
シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド filed Critical シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド
Publication of JP2024543496A publication Critical patent/JP2024543496A/ja
Publication of JP2024543496A5 publication Critical patent/JP2024543496A5/ja
Application granted granted Critical
Publication of JP7829035B2 publication Critical patent/JP7829035B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024528580A 2021-11-16 2022-11-15 アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法 Active JP7829035B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/130832 2021-11-16
CN2021130832 2021-11-16
CN2022081578 2022-03-18
CNPCT/CN2022/081578 2022-03-18
PCT/CN2022/131861 WO2023088227A1 (zh) 2021-11-16 2022-11-15 抑制血管紧张素原(agt)蛋白表达的组合物和方法

Publications (3)

Publication Number Publication Date
JP2024543496A JP2024543496A (ja) 2024-11-21
JP2024543496A5 JP2024543496A5 (https=) 2025-10-21
JP7829035B2 true JP7829035B2 (ja) 2026-03-12

Family

ID=86396260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528580A Active JP7829035B2 (ja) 2021-11-16 2022-11-15 アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法

Country Status (18)

Country Link
US (3) US20240084304A1 (https=)
EP (1) EP4435103A4 (https=)
JP (1) JP7829035B2 (https=)
KR (1) KR20240103025A9 (https=)
CN (1) CN116940682A (https=)
AU (1) AU2022394667A1 (https=)
CA (1) CA3238865A1 (https=)
CL (1) CL2024001429A1 (https=)
CO (1) CO2024006020A2 (https=)
CR (1) CR20240196A (https=)
DO (1) DOP2024000083A (https=)
EC (1) ECSP24036299A (https=)
IL (1) IL312811A (https=)
JO (1) JOP20240109A1 (https=)
MX (1) MX2024005862A (https=)
PE (1) PE20241933A1 (https=)
TW (1) TW202334422A (https=)
WO (1) WO2023088227A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
EP4562158A1 (en) 2023-06-13 2025-06-04 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen
WO2025007961A1 (zh) * 2023-07-06 2025-01-09 大睿生物 调控AGT表达的dsRNA分子
TW202509216A (zh) * 2023-07-14 2025-03-01 大陸商北京安龍生物醫藥有限公司 靶向血管收縮素原的寡核苷酸及其用途
CN119585432B (zh) * 2023-08-22 2025-08-12 成都先衍生物技术有限公司 一种靶向AGT基因表达的siRNA及其缀合物和用途
WO2025130862A1 (zh) * 2023-12-18 2025-06-26 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120350001A (zh) * 2024-01-22 2025-07-22 尧唐(上海)生物科技有限公司 靶向AGT基因的gRNA及其应用
CN119040330B (zh) * 2024-11-01 2025-03-04 北京悦康科创医药科技股份有限公司 一种调控AGT基因表达的siRNA及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522841A (ja) 2018-05-14 2021-09-02 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アンジオテンシノーゲン（ＡＧＴ）ｉＲＮＡ組成物及びその使用方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
EP0906123A4 (en) * 1996-03-15 1999-05-26 Univ Florida ANGIOTENSINOGEN mRNA SPECIFIC OLIGONUCLEOTIDES
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005116204A1 (ja) 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
EP1841464B1 (en) 2005-01-24 2012-06-27 Alnylam Pharmaceuticals Inc. Rnai modulation of the nogo-l or nogo-r gene and uses thereof
KR20080068019A (ko) 2005-09-15 2008-07-22 산타리스 팔마 에이/에스 아포지단백질-ｂ100 발현 억제용 ｒｎａ 길항제 화합물
CN101292034A (zh) 2005-09-15 2008-10-22 桑塔里斯制药公司 抑制apo-b100表达的rna拮抗化合物
WO2008137751A2 (en) 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
US11414664B2 (en) 2008-12-18 2022-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN103555722B (zh) 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
US20110196141A1 (en) 2009-09-07 2011-08-11 Council Of Scientific & Industrial Research Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides
TWI458493B (zh) 2009-09-25 2014-11-01 Iner Aec Executive Yuan 新穎肝標靶藥劑與合成方法
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012145582A2 (en) 2011-04-22 2012-10-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibitions of egfr by double-stranded rna
CN102260673A (zh) 2011-07-12 2011-11-30 深圳职业技术学院 靶向人血管紧张素原的rna干扰片段、表达载体与应用
SI3366775T2 (sl) 2011-11-18 2025-12-31 Alnylam Pharmaceuticals, Inc. Modificirana sredstva RNAI
EP3822352A3 (en) 2012-05-24 2021-11-03 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
WO2014018930A1 (en) * 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
TWI553017B (zh) 2012-12-28 2016-10-11 行政院原子能委員會核能研究所 新穎膽道掃描用造影劑及其製造方法
CN103103192A (zh) 2013-01-18 2013-05-15 深圳职业技术学院 靶向血管紧张素原的rna干扰片段、其表达载体、混合克隆细胞株及其应用
CA2900238A1 (en) 2013-02-22 2014-08-28 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
EP3065783A4 (en) 2013-11-06 2017-06-21 Merck Sharp & Dohme Corp. Dual molecular delivery of oligonucleotides and peptide containing conjugates
HUE052709T2 (hu) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
AU2015264038B2 (en) 2014-05-22 2021-02-11 Alnylam Pharmaceuticals, Inc. Angiotensinogen (AGT) iRNA compositions and methods of use thereof
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
DK3569711T3 (da) 2014-12-15 2021-02-22 Dicerna Pharmaceuticals Inc Ligandmodificerede dobbeltstrengede nukleinsyrer
CA2979703A1 (en) 2015-03-17 2016-09-22 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of factor xii
WO2016196111A1 (en) * 2015-06-01 2016-12-08 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting angiotensinogen (agt) and methods of use thereof
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN113817735A (zh) 2015-10-08 2021-12-21 Ionis制药公司 用于调节血管紧张素原表达的化合物和方法
CA3020585A1 (en) 2016-04-11 2017-10-19 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
SG11201901841TA (en) 2016-09-02 2019-03-28 Arrowhead Pharmaceuticals Inc Targeting ligands
US11504391B1 (en) 2016-11-23 2022-11-22 Alnylam Pharmaceuticals, Inc. Modified RNA agents with reduced off-target effect
DK3607069T3 (da) 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger
EP3649243A1 (en) 2017-07-07 2020-05-13 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12)
KR20240161202A (ko) 2017-09-11 2024-11-12 애로우헤드 파마슈티컬스 인코포레이티드 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
HRP20230127T1 (hr) 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiranje ekspresije lpa u stanici
IL276043B2 (en) 2018-01-29 2024-06-01 Hoffmann La Roche Process for the preparation of galnac oligonucleotide conjugates
WO2019217397A2 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for improving strand biased
PH12021550801B1 (en) 2018-11-13 2024-04-26 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
WO2020123410A1 (en) 2018-12-10 2020-06-18 Amgen Inc. CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US20200385713A1 (en) 2019-01-22 2020-12-10 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
EP3923989A1 (en) 2019-03-21 2021-12-22 Mitotherapeutix LLC Multivalent ligand clusters for targeted delivery of therapeutic agents
WO2020236526A1 (en) 2019-05-23 2020-11-26 Stratos Genomics, Inc. Translocation control elements, reporter codes, and further means for translocation control for use in nanopore sequencing
IL291251B1 (en) 2019-09-10 2026-02-01 Daiichi Sankyo Co Ltd Oligonucleotide-galnac conjugate for targeted delivery to the liver and method for its production
BR112022009216A2 (pt) 2019-11-13 2022-08-02 Alnylam Pharmaceuticals Inc Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
MX2022007005A (es) 2019-12-09 2022-08-25 Amgen Inc Construcciones de iarn y metodos para inhibir la expresion de lpa.
PE20221578A1 (es) 2020-03-06 2022-10-06 Aligos Therapeutics Inc Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas
US11649458B2 (en) * 2020-05-05 2023-05-16 University Of Kentucky Research Foundation Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome
MX2022014606A (es) 2020-05-22 2023-03-08 Wave Life Sciences Ltd Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
WO2022028457A1 (zh) 2020-08-04 2022-02-10 上海拓界生物医药科技有限公司 抑制凝血因子XI表达的siRNA、组合物及其医药用途
US12435336B2 (en) 2020-08-05 2025-10-07 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting LPA expression
WO2022079221A1 (en) 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
CN114763547A (zh) 2021-01-14 2022-07-19 施能康生物科技有限公司 靶向血管紧张素原的核酸及其用途
MX2023008469A (es) * 2021-01-22 2023-11-22 Alnylam Pharmaceuticals Inc Oligonucleotidos de doble hebra modificados.
EP4176061A1 (en) 2021-01-30 2023-05-10 E-Therapeutics plc Nucleic acids containing abasic nucleotides
WO2022232650A1 (en) 2021-04-30 2022-11-03 Ionis Pharmaceuticals, Inc. Methods for reducing agt expression
AU2022303164A1 (en) 2021-06-30 2024-01-18 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
EP4381071A1 (en) * 2021-08-04 2024-06-12 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing angiotensinogen (agt)
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
US20240401045A1 (en) 2021-10-01 2024-12-05 Adarx Pharmaceuticals, Inc. Angiotensinogen-modulating compositions and methods of use thereof
CN120775847A (zh) 2021-10-20 2025-10-14 厦门甘宝利生物医药有限公司 Agt抑制剂及其用途
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
US20240041913A1 (en) * 2022-04-01 2024-02-08 Adarx Pharmaceuticals, Inc. Angiotensinogen-modulating compositions and methods of use thereof
WO2024013334A1 (en) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of agt in a cell
KR20250046303A (ko) * 2022-08-05 2025-04-02 사네진 바이오 유에스에이 인크. 안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법
TW202430193A (zh) 2022-12-20 2024-08-01 美商靖因藥業（上海）有限公司 靶向agt之聚核酸分子及其用途
WO2024187193A2 (en) 2023-03-09 2024-09-12 Basecure Therapeutics Llc Compositions and methods for inhibition of expression of angiotensinogen (agt) genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522841A (ja) 2018-05-14 2021-09-02 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アンジオテンシノーゲン（ＡＧＴ）ｉＲＮＡ組成物及びその使用方法

Also Published As

Publication number Publication date
IL312811A (en) 2024-07-01
KR20240103025A9 (ko) 2025-12-10
CN116940682A (zh) 2023-10-24
TW202334422A (zh) 2023-09-01
CR20240196A (es) 2024-07-08
EP4435103A4 (en) 2025-11-26
US20260103705A1 (en) 2026-04-16
PE20241933A1 (es) 2024-09-24
US12534726B2 (en) 2026-01-27
KR20240103025A (ko) 2024-07-03
CL2024001429A1 (es) 2024-11-08
DOP2024000083A (es) 2024-08-15
JOP20240109A1 (ar) 2024-05-14
CO2024006020A2 (es) 2024-08-08
AU2022394667A1 (en) 2024-06-13
JP2024543496A (ja) 2024-11-21
WO2023088227A1 (zh) 2023-05-25
CA3238865A1 (en) 2023-05-25
US20250215429A1 (en) 2025-07-03
MX2024005862A (es) 2024-07-10
EP4435103A1 (en) 2024-09-25
US20240084304A1 (en) 2024-03-14
ECSP24036299A (es) 2024-07-31

Similar Documents

Publication Publication Date Title
JP7829035B2 (ja) アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法
JP7833044B2 (ja) タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法
TWI877520B (zh) 用於抑制血管生成素樣３（ａｎｇｐｔｌ３）蛋白表達的組合物和方法
TW202404615A (zh) 用於抑制黃嘌呤脫氫酶(xdh)的組合物和方法
TW202405170A (zh) 用於抑制補體成分c3蛋白表達的組合物和方法
KR20240111795A (ko) B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
US20250145999A1 (en) Compositions and methods for inhibiting expression of prekallikrein (pkk) protein
KR20260030856A (ko) 보체 인자 b(cfb) 발현을 억제하기 위한 조성물 및 방법
RU2854980C2 (ru) Композиции и способы ингибирования экспрессии ангиопоэтин-подобного белка 3 (angptl3)
HK40115058A (en) Composition and method for inhibiting angiotensinogen (agt) protein expression
HK40116126A (en) Composition and method for inhibiting expression of protein lpa(apo(a))
HK40109544A (zh) 用於抑制前激肽释放酶(pkk)蛋白表达的组合物和方法
CN122003498A (zh) 抑制淀粉样前体蛋白(app)表达的组合物和方法
HK40096008A (zh) 用於抑制血管生成素样3(angptl3)蛋白表达的组合物和方法
TW202516009A (zh) 抑制澱粉樣前體蛋白(app)表達的組合物和方法
TW202527968A (zh) 用於抑制跨膜絲氨酸蛋白酶6（tmprss6）表達的組合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251010

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260302

R150 Certificate of patent or registration of utility model

Ref document number: 7829035

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150